September 8, 2010 ·
4 comments
Rhonda Napier joined Thought Leader Select as a research manager in the spring of 2010, after serving the company for two years as a researcher. A graduate of West Virginia University (bachelor’s degree in exercise physiology) and Marshall University (master’s degree in adult fitness and cardiac rehabilitation), Rhonda worked in research and clinical practice as an exercise physiologist for 13 years.
During her time at the Ohio State University College of Nursing, Napier led National Institutes of Health-funded research on the effects of exercise on hypertensive women. More recently, her work at the Gillings School for Global Public Health at the University of North Carolina at Chapel Hill focused on quality and access to healthcare.
The Thought Leader Select Blog sat down with Rhonda to discuss her skills and experiences, as well as her contribution to the work of Thought Leader Select.
TLS Blog: Good afternoon, Rhonda. Why did you join Thought Leader Select?
Rhonda Napier: I had the good fortune of meeting the company’s leadership team through my husband, Chris, after he became acquainted with them. That was back in 2008, and they had an opportunity for me to come into the company as a researcher. The idea of exclusively doing research for me was odd, because I had been a clinician for so many years—but I became ... read more »
TAGS: 
biopharmaceutical biotechnology cardiology clinical trials excercise physiology Gillings School for Global Public Health health care professionals healthcare access healthcare quality hypertension key opinion leaders KOL engagement KOL identification KOL mapping KOL profiling KOL research KOLs Marshall University medicine National Institutes of Health Ohio State Buckeyes Ohio State University College of Nursing patient advocacy patient care pharmaceutical physicians Rhonda Napier Thought Leader Select thought leaders University of North Carolina at Chapel Hill West Virginia University
June 3, 2010 ·
1 comment
Industry Insights from Paul Meade, M. Sc, MPH
During my recent studies for an ethics certificate, I encountered several ethical issues that stimulated my thinking about the future of healthcare.
I would like to address an ethical issue that I feel will dominate the healthcare landscape for the next several decades, in the area of genetics.
With the completion of the Human Genome Project and the mapping of mankind’s blueprint of life, we are beginning to gain a greater understanding of what makes us human. One logical extension of this “knowledge of life” is the ability to control or manipulate life itself. Gene therapy will give us the ability to not only modify our genetic predisposition to diseases, but also to enhance lifestyle abilities. No one would argue the ability to change one base-pair and eliminate Huntington’s disease from an unborn child, but how far is one willing to go to be taller, more athletic, have a gift of music, or become a genius. Who will decide what genetic alterations are acceptable to a society? And who will qualify to have such manipulations—only those that can afford to pay?
The ability to manipulate our genome is the ability to control human evolution itself. No more will we need to rely on random chance and Darwinian principles, such as natural selection–we will be able ... read more »
TAGS: bioethics Charles Darwin evolution gene therapy genetic manipulation genetics genotypic expression Gillings School for Global Public Health healthcare Human Genome Project Huntington's disease natural selection Paul Meade phenotypic expression Thought Leader Select University of North Carolina at Chapel Hill
June 2, 2010 ·
Leave a comment
Paul Meade, a 25-year veteran of the pharmaceutical industry, founded Thought Leader Select in 2006. Throughout his career, Paul served in several leadership positions in sales, marketing, and strategic planning, culminating in his role of director of worldwide commercial development for predictive medicine at GlaxoSmithKline.
After leaving GSK, Paul launched two companies, Clear Point Health, in 2005, and Thought Leader Select, in 2006. Paul’s work with these two companies entails marketing planning, consulting for research and development and clinical operations, as well as his breakthrough work with medical expert collaborations for the pharmaceutical industry.
The Thought Leader Select Blog sat down with Paul to discuss his industry experience and his professional contribution to Thought Leader Select.
TLS Blog: Good afternoon, Paul. Why did you start Thought Leader Select?
Paul Meade: About a year before starting the company, I had begun consulting with the health industry with my partner, Lisa Smith, through our company, Clear Point Health. We were taking on a number of projects, working with medical affairs teams, marketing teams, and research and development groups within the industry.
One of our large clients came to me and told me that, even though they’d been working with thought leaders for over ten years, they realized how little they really knew about them. When they sat down to consolidate all of their knowledge about their medical ... read more »
TAGS: advisory boards biotechnology Civil Air Patrol Clear Point Health clinical operations clinical research clinical trials commercial development committees Gillings School for Global Public Health GlaxoSmithKline Johns Hopkins University key opinion leaders KOL engagement KOL identification KOL profiling KOLs marketing planning master of public health medical ethics medical experts Merck Paul Meade pharmaceutical pharmaceutical marketing pharmaceutical sales predictive medicine public health publishing research and development research methodology The Immortal Life of Henrietta Lacks Thought Leader Select thought leaders transparency United States Air Force University of North Carolina at Chapel Hill
